东曜药业有限公司 TOT BIOPHARM
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
SUCCESSFUL PASSING OF EU QP AUDIT ON TOT BIOPHARM'S COMMERCIAL PRODUCTION BASE FOR MONOCLONAL ANTIBODY DRUG SUBSTANCES AND ANTIBODY DRUG CONJUGATES 2022-10-27 08:00
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares 2022-06-02 08:00
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China 2021-12-02 08:00
TOT BIOPHARM Anounces 2021 Interim Results 2021-08-13 10:59
TOT BIOPHARM raises US$102 million in Series B Financing Round 2018-08-08 19:00
TOT BIOPHARM's 16,000L-capacity monoclonal antibodies production base put into operation 2018-06-21 10:40
1